Sen-Jam Pharmaceutical announced a partnership with TASK Clinical, a global contract research organization (CRO). Under the agreement, TASK Clinical will fund two-thirds of the upcoming Phase 3 clinical trial for SJP-001 in exchange for equity — an exceptionally rare commitment that significantly de-risks development, enhances investor confidence, and strengthens the program for global licensing opportunities.
This milestone follows Sen-Jam's recent announcement appointing Rute Fernandes, a seasoned global life-sciences executive with leadership roles across Takeda, Shire, and Novartis, as Executive Advisor to accelerate commercialization pathways.
Sen-Jam now benefits from a vertically integrated development ecosystem:
- TASK Clinical providing clinical leadership and majority funding of Phase 3
- KVK Tech, Sen-Jam's established corporate venture partner/CMO, driving formulation, CMC, and FDA submission readiness
- Rute Fernandes guiding global market expansion and commercialization strategy
KVK Tech has made significant progress in the formulation development and CMC work for SJP-001, including the manufacturing of GMP batches. Upon completion of the ongoing Phase 2 dose-ranging study, KVK Tech will finalize the FDA submission batches, enabling a rapid transition into Phase 3 and subsequent regulatory filing.